宋俊燕　张毅

摘 要：目的 對急性ST段抬高型心肌梗死应用重组人尿激酶原治疗的效果及可能引发的并发症进行探讨。方法 选取孝义市人民医院2016年12月～2018年3月收治的急性ST段抬高型心肌梗死患者共80例，将其随机分组，给予重组人尿激酶原治疗者设定为观察组，给予尿激酶治疗者设定为对照组，每组40例。ST段回落≥50%的发生率、冠状动脉血管再通率、治疗2 h、24 h后纤溶酶、纤溶酶原及纤维蛋白原水平的分析。结果 观察组ST段回落≥50%的发生率为92.50%，观察组冠状动脉血管再通率为87.50%，对照组分别为65.00%、62.50%，差异有统计学意义（P<0.05）。治疗2 h、24 h观察组纤溶酶、纤溶酶原及纤维蛋白原水平均高于对照组，差异有统计学意义（P<0.05）。观察组并发症发生率5.00%，低于对照组的20.00%，差异有统计学意义（P<0.05）。结论 临床对急性ST段抬高型心肌梗死患者应用重组人尿激酶原治疗，可有效提升冠状动脉血管再通率，效果显著且并发症发生率低。

关键词：重组人尿激酶原；急性ST段抬高型；心肌梗死；溶栓

中图分类号：R542.2+2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.11.042

文章编号：1006-1959（2018）11-0133-03

Therapeutic Efficacy and Complications of Recombinant Human Pro-urokinase in Acute ST-elevation Myocardial Infarction

SONG Jun-yan，ZHANG Yi

（Department of Cardiology，People's Hospital of Xiaoyi，Xiaoyi 032300，Shanxi，China）

Abstract：Objective To investigate the effect of recombinant human pro-urokinase therapy and the possible complications of acute ST-segment elevation myocardial infarction.Methods A total of 80 patients with acute ST segment elevation myocardial infarction who were admitted from December 2016 to March 2018 in Xiaoyi city People's Hospital were selected and randomized into groups.The patients who received recombinant human pro-urokinase therapy were assigned to the observation group and those who received urokinase therapy were assigned to the control group，with 40 patients in each group.The incidence of ≥50% drop in ST segment， coronary artery recanalization rate，analysis of plasmin，plasminogen and fibrinogen levels after 2 h and 24 h treatment.Results The incidence rate of≥50% in the observation group was 92.50% in the observation group，87.50% in the observation group，the control group was 65.00% and 62.50% respectively，and the difference was statistically significant（P<0.05）.The plasmin，plasminogen and fibrinogen levels in the observation group were higher than those in the control group at 2 h and 24 h after treatment，the difference was statistically significant（P<0.05）.The incidence of complications in the observation group was 5.00%，which was lower than that in the control group 20.00%，the difference was statistically significant（P<0.05）.Conclusion The clinical application of recombinant human pro-urokinase in acute ST-segment elevation myocardial infarction patients can effectively increase the rate of coronary artery vascular recanalization with significant effect and low complication rate.

Key words：Recombinant human pro-urokinase；Acute ST elevation；Myocardial infarction；Thrombolysis

急性心肌梗死（acute myocardial infarction，AMI）属于临床常见病，近年来，发病率明显升高[1]。以往临床采用尿激酶治疗心肌梗死，其疗效有限，方案推广意义不大。随着医学的深入研究，当前，临床采用重组人尿激酶原治疗急性心肌梗死，该药是一种新的溶栓良药，有效克服了尿激酶的不足之处。本组实验选取我院2016年12月～2018年3月收治的急性ST段抬高型心肌梗死患者共80例，分别给予不同治疗方案，旨在进一步探讨急性ST段抬高型心肌梗死治疗中重组人尿激酶原的应用效果，为临床用药提供合理的依据。

1资料与方法

1.1一般资料 选取孝义市人民医院2016年12月～2018年3月收治的急性ST段抬高型心肌梗死患者共80例作为研究样本，将其按数字随机分为观察组与对照组，每组40例。观察组男性23例，女性17例，年龄43～79岁，平均年龄（62.05±0.67）岁，梗死部位：下壁8例，前壁13例，右室梗死10例，高侧壁9例；……